The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE President receives call from Russian President
UAE intercepts 12 missiles and 36 drones on Tuesday
UAE joins UN Human Rights Council consultative group
Abdullah bin Zayed, Greek Defence Minister discuss Iran developments
Economy Minister confirms stable food prices, secure supply
UAE extends distance learning for universities until April 17
Dubai's KHDA opens applications for student scholarship programme
UAE President holds talks with Qatar's Emir in Abu Dhabi
